FDA's Real-Time Trials Could Speed New Drugs to Patients

Waiting years for a promising treatment to clear clinical trials could soon become history, thanks to a bold FDA experiment that's already showing results.

The Food and Drug Administration announced it has successfully launched two proof-of-concept trials that transmit patient data directly to regulators in real time. Instead of waiting months or years for sponsors to analyze and submit results, FDA scientists can now see safety signals and treatment outcomes as they happen.

The shift addresses a major bottleneck in drug development. For 60 years, clinical trials have followed the same slow pattern: research sites collect data, sponsors analyze it, then submit findings to the FDA. This process can take years, even when early results look promising.

AstraZeneca and Amgen are leading the charge with the first real-time trials. AstraZeneca's Phase 2 study focuses on patients with a type of lymphoma, while Amgen is testing treatments for small cell lung cancer. Both companies worked with the FDA to set up systems that share data continuously.

The technology behind this breakthrough comes from recent advances in artificial intelligence and data science. These tools make it possible to validate and share trial information securely as it happens, something that wasn't feasible just a few years ago.

"We have to consider our processes from the standpoint of a patient awaiting a potentially powerful treatment," said Chief AI Officer Jeremy Walsh. The agency has already received and confirmed data signals from AstraZeneca's trial through its partner Paradigm Health.

Why This Inspires

This initiative represents more than faster paperwork. It's about fundamentally rethinking how we get treatments to people who need them most.

Currently, clinical trials pause between phases while sponsors prepare new protocols and wait for regulatory approval. These gaps slow progress even when early results show promise. Real-time monitoring could eliminate many of those delays, creating truly continuous trials from early testing through final approval.

The FDA is calling this approach transformative for the entire clinical trials ecosystem. By catching safety concerns earlier and identifying effective treatments faster, the system protects patients while accelerating access to breakthrough therapies.

Commissioner Marty Makary says the ultimate goal is running real-time, continuous trials across all phases of drug development. The agency is now seeking public input on expanding the program through a larger pilot starting this summer.

For patients with cancer, rare diseases, or other serious conditions, every month matters. This new approach could turn years of waiting into months, bringing hope within reach for thousands who can't afford to wait.